Penumbra, Inc.
Moat Score — Penumbra, Inc.
Total Moat Score
13 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Penumbra holds a deep portfolio of thrombectomy device IP and FDA clearances built since 2004, with first-mover clinical credibility in aspiration-based clot removal that is difficult for new entrants to replicate quickly. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | In-house manufacturing at its Alameda and Roseville facilities gives Penumbra tight cost and quality control, but it does not have the raw purchasing/manufacturing scale of giants like Medtronic or Boston Scientific. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | Clinically differentiated thrombectomy devices with physician loyalty support premium pricing versus commodity vascular devices, evidenced by expanding operating margins (operating income rose from $6.1M to $73.6M on 25% revenue growth). |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Medical device adoption has no network effect; a hospital's or physician's experience with Penumbra's devices doesn't improve because more hospitals use them, beyond ordinary peer-reputation effects. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 3 / 5 | Physicians trained and comfortable with specific thrombectomy techniques and devices are reluctant to switch given the procedural stakes (stroke, limb ischemia), and hospital purchasing/credentialing processes add further friction to changing suppliers. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The vascular device market supports several large, well-capitalized competitors (Boston Scientific, Medtronic, Stryker, Terumo, Inari), so while sub-niches like aspiration thrombectomy are more concentrated, the space overall is not an efficient-scale oligopoly. |